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ABSTRACT
Post-transplantation cutaneous lymphoproliferative diseases (PTCLD) are rare, with 29 cases 
have so far been reported in the literature—only 4 cases underwent cardiac transplantation. 
Herein, we report on, to the best of our knowledge, the first case in the English literature of pri-
mary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma in a cardiac 
transplant recipient.
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INTRODUCTION
Heart transplantation (HT) is the treat-ment of choice for patients with end-stage heart failure. The outcome of 
HT has improved dramatically over the past 
few decades, with increased number of patients 
receiving heart transplant and living with it. 
Post-transplant lymphoproliferative disorder 
(PTLD) is an increasingly recognized condi-
tion as the number of solid organ transplant 
recipients increases. In Iran, totally 775 pa-
tients underwent HT since 1995.
CASE REPORT
In January 2011, an 18-year-old man with a 
history of progressive dilated cardiomyopa-
thy underwent orthotopic heart transplanta-
tion. Standard triple-agent immunosuppres-
sive therapy (cyclosporine, prednisolone, and 
azathioprine) was begun after the surgery. In 
May 2012, the patient developed painless left 
inguinal mass that expanded in size over the 
previous four months. Examination of the skin 
revealed a reddish and ulcerative mass, about 3 
cm in diameter on the left inguinal area (Fig. 1). 
There is no inguinal, axillary, or neck lymph-
adenopathy. The patient underwent wide-local 
excision of the mass. The specimen excised 
Figure 1: Appearance of the lesion: reddish, ul-
cerated, approximately 3 cm in diameter
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revealed compact proliferation of pleomorphic 
small to medium sized lymphoid cells with ir-
regular nuclear border and scanty cytoplasm. 
The lymphoid infiltration extended into deep 
dermis. Immunohistochemical (IHC) staining 
showed that the neoplastic cells were CD4 and 
CD3 positive with aberrant loss of CD5 and 
negative B-cell markers (CD20, CD79 α, and 
PUX5) in favor of post-transplantation cuta-
neous lymphoproliferative disease (PTCLD) 
(Fig 2). Examination of a peripheral blood 
smear was normal. Viral studies revealed no 
evidence of infection with Epstein-Barr virus 
(EBV) and Human T-cell lymphotropic virus 
type 1 (HTLV-1). Staging, including comput-
ed tomography of the brain, chest, abdomen, 
and pelvis with and without contrast, was per-
formed and were unremarkable. Bone-marrow 
biopsy was normal. His cyclosporine dosage 
was reduced. After five years of follow-up, he 
was alive and doing well.
DISCUSSION
PTLD occurs in approximately 1%–2% of 
transplant recipient [1]. Most cases are of B-
cell lymphoma and are associated with EBV. 
The time between transplantation and devel-
opment of PTLD is variable ranging from one 
month to seven years, mostly occurring with-
in one year [2]. Estimates of PTLD frequency 
in recipients of different types of allografts are 
1%–2% for kidney, 2% for liver, 2%–10% for 
heart,5%–9% for heart and lung, and 19% for 
intestine [3, 4]. T-cell lymphoma is more com-
mon in Asian than Western countries, usually 
affects adults with a higher tendency in men. 
Reduction of immune surveillance, chronic an-
tigenic stimulation by the transplanted organ 
and direct oncogenic potential of immunosup-
pressive drugs could be considered risk factors 
for PTLD in transplant recipients. The skin 
is an unusual site of primary or secondary ex-
tranodal involvement of PTLD. Various types 
of post-transplantation primary and second-
ary cutaneous T-cell lymphoma, according 
to the European Organization for Research 
and Treatment (EORTC) classification, have 
been rarely reported in the literature. Primary 
cutaneous small-to-medium sized CD4+ pleo-
morphic T-cell lymphoma (PCSM-TCL) is 
very rare. The presentation of PCSM-TCL is 
heterogeneous and includes solitary papules, 
nodules, plaques, and tumors [5]. The prog-
nosis is favorable, but the best treatment has 
not yet been defined. In conclusion, transplan-
tation surgeons should be aware of possibility 
of PTCLD in cardiac transplant recipients.
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Figure 2: Immunohistochemical staining of the 
lesion: CD4+
Cutaneous Lymphoma after Heart Tx
